|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of mhc class ii associated p41 ii fragment complex with cathepsin l
|
|
Structure:
|
 |
Protein (cathepsin l: heavy chain). Chain: a, c. Protein (cathepsin l: light chain). Chain: b, d. Protein (invariant chain). Chain: i, j. Fragment: thyroglobulin type-1 domain. Synonym: ii fragment, cd74 fragment
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Organ: kidney. Organ: kidney
|
|
Biol. unit:
|
 |
Trimer (from
)
|
|
Resolution:
|
 |
|
2.00Å
|
R-factor:
|
0.182
|
R-free:
|
0.213
|
|
|
Authors:
|
 |
G.Guncar,G.Pungercic,I.Klemencic,V.Turk,D.Turk
|
Key ref:
|
 |
G.Guncar
et al.
(1999).
Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S.
Embo J,
18,
793-803.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
07-Jan-99
|
Release date:
|
12-Jan-00
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P07711
(CATL1_HUMAN) -
Cathepsin L1
|
|
|
|
Seq: Struc:
|
 |
 |
 |
333 a.a.
175 a.a.
|
|
|
|
|
|
|
 |
 |
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chains A, B, C, D:
E.C.3.4.22.15
- Cathepsin L.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Specificity close to that of papain. As compared to cathepsin B, cathepsin L exhibits higher activity towards protein substrates, but has little activity on Z-Arg-Arg-NHMec, and no peptidyl-dipeptidase activity.
|
 |
 |
 |
 |
 |
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Biological process
|
proteolysis
|
1 term
|
 |
|
Biochemical function
|
cysteine-type peptidase activity
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Embo J
18:793-803
(1999)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S.
|
|
G.Guncar,
G.Pungercic,
I.Klemencic,
V.Turk,
D.Turk.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The lysosomal cysteine proteases cathepsins S and L play crucial roles in the
degradation of the invariant chain during maturation of MHC class II molecules
and antigen processing. The p41 form of the invariant chain includes a fragment
which specifically inhibits cathepsin L but not S. The crystal structure of the
p41 fragment, a homologue of the thyroglobulin type-1 domains, has been
determined at 2.0 A resolution in complex with cathepsin L. The structure of the
p41 fragment demonstrates a novel fold, consisting of two subdomains, each
stabilized by disulfide bridges. The first subdomain is an
alpha-helix-beta-strand arrangement, whereas the second subdomain has a
predominantly beta-strand arrangement. The wedge shape and three-loop
arrangement of the p41 fragment bound to the active site cleft of cathepsin L
are reminiscent of the inhibitory edge of cystatins, thus demonstrating the
first example of convergent evolution observed in cysteine protease inhibitors.
However, the different fold of the p41 fragment results in additional contacts
with the top of the R-domain of the enzymes, which defines the
specificity-determining S2 and S1' substrate-binding sites. This enables
inhibitors based on the thyroglobulin type-1 domain fold, in contrast to the
rather non-selective cystatins, to exhibit specificity for their target enzymes.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2 Schematic representation of the p41 fragment fold and
its contacts with cathepsin L. p41 fragment residues are
represented as circles, and interacting cathepsin L residues as
squares. Dark grey shaded circles represent the C–CWC–C
building element. Disulfide bridges are represented as dashed
winding lines, hydrogen bonds and electrostatic interactions as
dashed lines, and hydrophobic interactions as thin dotted lines.
The Asn240F residue was observed in the electron density map to
be glycosylated and is represented by a triangle.
|
 |
Figure 7.
Figure 7 Structural role of the CWC sequence motif. The CWC
sequence forms the core of the interface between the subdomains
of the p41 fragment (thick lines) and of the superimposed
fibrin-binding finger domain of tissue-type plasminogen
activator (thin lines) (Downing et al., 1992). The figure was
prepared with the program MAIN (Turk, 1992).
|
 |
|
|
|
| |
The above figures are
reprinted
from an Open Access publication published by Macmillan Publishers Ltd:
Embo J
(1999,
18,
793-803)
copyright 1999.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
Google scholar
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.Renko,
J.Sabotic,
M.Mihelic,
J.Brzin,
J.Kos,
and
D.Turk
(2010).
Versatile loops in mycocypins inhibit three protease families.
|
| |
J Biol Chem, 285,
308-316.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Renko,
U.Požgan,
D.Majera,
and
D.Turk
(2010).
Stefin A displaces the occluding loop of cathepsin B only by as much as required to bind to the active site cleft.
|
| |
FEBS J, 277,
4338-4345.
|
 |
|
|
|
|
 |
V.Stoka,
and
V.Turk
(2010).
A structural network associated with the kallikrein-kinin and renin-angiotensin systems.
|
| |
Biol Chem, 391,
443-454.
|
 |
|
|
|
|
 |
M.Mihelic,
A.Dobersek,
G.Guncar,
and
D.Turk
(2008).
Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation.
|
| |
J Biol Chem, 283,
14453-14460.
|
 |
|
|
|
|
 |
M.Mihelic,
and
D.Turk
(2007).
Two decades of thyroglobulin type-1 domain research.
|
| |
Biol Chem, 388,
1123-1130.
|
 |
|
|
|
|
 |
S.Q.Wang,
Q.S.Du,
K.Zhao,
A.X.Li,
D.Q.Wei,
and
K.C.Chou
(2007).
Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy.
|
| |
Amino Acids, 33,
129-135.
|
 |
|
|
|
|
 |
S.X.Wang,
K.C.Pandey,
J.Scharfstein,
J.Whisstock,
R.K.Huang,
J.Jacobelli,
R.J.Fletterick,
P.J.Rosenthal,
M.Abrahamson,
L.S.Brinen,
A.Rossi,
A.Sali,
and
J.H.McKerrow
(2007).
The structure of chagasin in complex with a cysteine protease clarifies the binding mode and evolution of an inhibitor family.
|
| |
Structure, 15,
535-543.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.Zavasnik-Bergant,
and
B.Turk
(2007).
Cysteine proteases: destruction ability versus immunomodulation capacity in immune cells.
|
| |
Biol Chem, 388,
1141-1149.
|
 |
|
|
|
|
 |
B.O.Smith,
N.C.Picken,
G.D.Westrop,
K.Bromek,
J.C.Mottram,
and
G.H.Coombs
(2006).
The structure of Leishmania mexicana ICP provides evidence for convergent evolution of cysteine peptidase inhibitors.
|
| |
J Biol Chem, 281,
5821-5828.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Tardy,
P.Codogno,
H.Autefage,
T.Levade,
and
N.Andrieu-Abadie
(2006).
Lysosomes and lysosomal proteins in cancer cell death (new players of an old struggle).
|
| |
Biochim Biophys Acta, 1765,
101-125.
|
 |
|
|
|
|
 |
N.Obermajer,
B.Doljak,
and
J.Kos
(2006).
Cysteine cathepsins: regulators of antitumour immune response.
|
| |
Expert Opin Biol Ther, 6,
1295-1309.
|
 |
|
|
|
|
 |
T.Zavasnik-Bergant,
and
B.Turk
(2006).
Cysteine cathepsins in the immune response.
|
| |
Tissue Antigens, 67,
349-355.
|
 |
|
|
|
|
 |
A.Sala,
S.Capaldi,
M.Campagnoli,
B.Faggion,
S.Labò,
M.Perduca,
A.Romano,
M.E.Carrizo,
M.Valli,
L.Visai,
L.Minchiotti,
M.Galliano,
and
H.L.Monaco
(2005).
Structure and properties of the C-terminal domain of insulin-like growth factor-binding protein-1 isolated from human amniotic fluid.
|
| |
J Biol Chem, 280,
29812-29819.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.Otlewski,
F.Jelen,
M.Zakrzewska,
and
A.Oleksy
(2005).
The many faces of protease-protein inhibitor interaction.
|
| |
EMBO J, 24,
1303-1310.
|
 |
|
|
|
|
 |
J.T.Christeller
(2005).
Evolutionary mechanisms acting on proteinase inhibitor variability.
|
| |
FEBS J, 272,
5710-5722.
|
 |
|
|
|
|
 |
L.C.Hsing,
and
A.Y.Rudensky
(2005).
The lysosomal cysteine proteases in MHC class II antigen presentation.
|
| |
Immunol Rev, 207,
229-241.
|
 |
|
|
|
|
 |
L.Puzer,
S.S.Cotrin,
M.H.Cezari,
I.Y.Hirata,
M.A.Juliano,
I.Stefe,
D.Turk,
B.Turk,
L.Juliano,
and
A.K.Carmona
(2005).
Recombinant human cathepsin X is a carboxymonopeptidase only: a comparison with cathepsins B and L.
|
| |
Biol Chem, 386,
1191-1195.
|
 |
|
|
|
|
 |
P.Meh,
M.Pavsic,
V.Turk,
A.Baici,
and
B.Lenarcic
(2005).
Dual concentration-dependent activity of thyroglobulin type-1 domain of testican: specific inhibitor and substrate of cathepsin L.
|
| |
Biol Chem, 386,
75-83.
|
 |
|
|
|
|
 |
T.F.Kagawa,
P.W.O'toole,
and
J.C.Cooney
(2005).
SpeB-Spi: a novel protease-inhibitor pair from Streptococcus pyogenes.
|
| |
Mol Microbiol, 57,
650-666.
|
 |
|
|
|
|
 |
A.Rossi,
Q.Deveraux,
B.Turk,
and
A.Sali
(2004).
Comprehensive search for cysteine cathepsins in the human genome.
|
| |
Biol Chem, 385,
363-372.
|
 |
|
|
|
|
 |
C.Watts
(2004).
The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules.
|
| |
Nat Immunol, 5,
685-692.
|
 |
|
|
|
|
 |
G.Croce,
A.Frache,
M.Milanesio,
L.Marchese,
M.Causà,
D.Viterbo,
A.Barbaglia,
V.Bolis,
G.Bavestrello,
C.Cerrano,
U.Benatti,
M.Pozzolini,
M.Giovine,
and
H.Amenitsch
(2004).
Structural characterization of siliceous spicules from marine sponges.
|
| |
Biophys J, 86,
526-534.
|
 |
|
|
|
|
 |
M.Fonovic,
D.Brömme,
V.Turk,
and
B.Turk
(2004).
Human cathepsin F: expression in baculovirus system, characterization and inhibition by protein inhibitors.
|
| |
Biol Chem, 385,
505-509.
|
 |
|
|
|
|
 |
B.Turk,
H.Fritz,
and
V.Turk
(2003).
Vito Turk--30 years of research on cysteine proteases and their inhibitors.
|
| |
Biol Chem, 384,
833-836.
|
 |
|
|
|
|
 |
C.Beers,
K.Honey,
S.Fink,
K.Forbush,
and
A.Rudensky
(2003).
Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages.
|
| |
J Exp Med, 197,
169-179.
|
 |
|
|
|
|
 |
D.Turk,
and
G.Guncar
(2003).
Lysosomal cysteine proteases (cathepsins): promising drug targets.
|
| |
Acta Crystallogr D Biol Crystallogr, 59,
203-213.
|
 |
|
|
|
|
 |
J.P.Bocock,
C.J.Edgell,
H.S.Marr,
and
A.H.Erickson
(2003).
Human proteoglycan testican-1 inhibits the lysosomal cysteine protease cathepsin L.
|
| |
Eur J Biochem, 270,
4008-4015.
|
 |
|
|
|
|
 |
K.Honey,
and
A.Y.Rudensky
(2003).
Lysosomal cysteine proteases regulate antigen presentation.
|
| |
Nat Rev Immunol, 3,
472-482.
|
 |
|
|
|
|
 |
M.Sulpizi,
A.Laio,
J.VandeVondele,
A.Cattaneo,
U.Rothlisberger,
and
P.Carloni
(2003).
Reaction mechanism of caspases: insights from QM/MM Car-Parrinello simulations.
|
| |
Proteins, 52,
212-224.
|
 |
|
|
|
|
 |
M.Sulpizi,
U.Rothlisberger,
and
P.Carloni
(2003).
Molecular dynamics studies of caspase-3.
|
| |
Biophys J, 84,
2207-2215.
|
 |
|
|
|
|
 |
A.M.Lennon-Duménil,
A.H.Bakker,
P.Wolf-Bryant,
H.L.Ploegh,
and
C.Lagaudrière-Gesbert
(2002).
A closer look at proteolysis and MHC-class-II-restricted antigen presentation.
|
| |
Curr Opin Immunol, 14,
15-21.
|
 |
|
|
|
|
 |
C.Vannahme,
N.Smyth,
N.Miosge,
S.Gösling,
C.Frie,
M.Paulsson,
P.Maurer,
and
U.Hartmann
(2002).
Characterization of SMOC-1, a novel modular calcium-binding protein in basement membranes.
|
| |
J Biol Chem, 277,
37977-37986.
|
 |
|
|
|
|
 |
D.C.Greenbaum,
W.D.Arnold,
F.Lu,
L.Hayrapetian,
A.Baruch,
J.Krumrine,
S.Toba,
K.Chehade,
D.Brömme,
I.D.Kuntz,
and
M.Bogyo
(2002).
Small molecule affinity fingerprinting. A tool for enzyme family subclassification, target identification, and inhibitor design.
|
| |
Chem Biol, 9,
1085-1094.
|
 |
|
|
|
|
 |
D.J.Rigden,
V.V.Mosolov,
and
M.Y.Galperin
(2002).
Sequence conservation in the chagasin family suggests a common trend in cysteine proteinase binding by unrelated protein inhibitors.
|
| |
Protein Sci, 11,
1971-1977.
|
 |
|
|
|
|
 |
E.Fiebiger,
R.Maehr,
J.Villadangos,
E.Weber,
A.Erickson,
E.Bikoff,
H.L.Ploegh,
and
A.M.Lennon-Duménil
(2002).
Invariant chain controls the activity of extracellular cathepsin L.
|
| |
J Exp Med, 196,
1263-1269.
|
 |
|
|
|
|
 |
G.Pungercic,
I.Dolenc,
M.Dolinar,
T.Bevec,
S.Jenko,
S.Kolaric,
and
V.Turk
(2002).
Individual recombinant thyroglobulin type-1 domains are substrates for lysosomal cysteine proteinases.
|
| |
Biol Chem, 383,
1809-1812.
|
 |
|
|
|
|
 |
J.P.Turkenburg,
M.B.Lamers,
A.M.Brzozowski,
L.M.Wright,
R.E.Hubbard,
S.L.Sturt,
and
D.H.Williams
(2002).
Structure of a Cys25-->Ser mutant of human cathepsin S.
|
| |
Acta Crystallogr D Biol Crystallogr, 58,
451-455.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.M.Lennon-Duménil,
R.A.Roberts,
K.Valentijn,
C.Driessen,
H.S.Overkleeft,
A.Erickson,
P.J.Peters,
E.Bikoff,
H.L.Ploegh,
and
P.Wolf Bryant
(2001).
The p41 isoform of invariant chain is a chaperone for cathepsin L.
|
| |
EMBO J, 20,
4055-4064.
|
 |
|
|
|
|
 |
C.Watts
(2001).
Antigen processing in the endocytic compartment.
|
| |
Curr Opin Immunol, 13,
26-31.
|
 |
|
|
|
|
 |
J.Kos,
A.Sekirnik,
G.Kopitar,
N.Cimerman,
K.Kayser,
A.Stremmer,
W.Fiehn,
and
B.Werle
(2001).
Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis.
|
| |
Br J Cancer, 85,
1193-1200.
|
 |
|
|
|
|
 |
K.Brix,
M.Linke,
C.Tepel,
and
V.Herzog
(2001).
Cysteine proteinases mediate extracellular prohormone processing in the thyroid.
|
| |
Biol Chem, 382,
717-725.
|
 |
|
|
|
|
 |
N.Kopitar-Jerala,
T.Bevec,
D.Barlic-Maganja,
F.Gubensek,
and
V.Turk
(2001).
Anti-cathepsin L monoclonal antibodies that distinguish cathepsin L from cathepsin V.
|
| |
Biol Chem, 382,
867-870.
|
 |
|
|
|
|
 |
V.Turk,
B.Turk,
and
D.Turk
(2001).
Lysosomal cysteine proteases: facts and opportunities.
|
| |
EMBO J, 20,
4629-4633.
|
 |
|
|
|
|
 |
V.Zavasnik-Bergant,
A.Sekirnik,
R.Golouh,
V.Turk,
and
J.Kos
(2001).
Immunochemical localisation of cathepsin S, cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue.
|
| |
Biol Chem, 382,
799-804.
|
 |
|
|
|
|
 |
G.Guncar,
I.Klemencic,
B.Turk,
V.Turk,
A.Karaoglanovic-Carmona,
L.Juliano,
and
D.Turk
(2000).
Crystal structure of cathepsin X: a flip-flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity of the protease.
|
| |
Structure, 8,
305-313.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Galesa,
B.Strukelj,
S.Bavec,
V.Turk,
and
B.Lenarcic
(2000).
Cloning and expression of functional equistatin.
|
| |
Biol Chem, 381,
85-88.
|
 |
|
|
|
|
 |
R.Busch,
R.C.Doebele,
N.S.Patil,
A.Pashine,
and
E.D.Mellins
(2000).
Accessory molecules for MHC class II peptide loading.
|
| |
Curr Opin Immunol, 12,
99.
|
 |
|
|
|
|
 |
R.J.Riese,
and
H.A.Chapman
(2000).
Cathepsins and compartmentalization in antigen presentation.
|
| |
Curr Opin Immunol, 12,
107-113.
|
 |
|
|
|
|
 |
S.Estrada,
S.T.Olson,
E.Raub-Segall,
and
I.Björk
(2000).
The N-terminal region of cystatin A (stefin A) binds to papain subsequent to the two hairpin loops of the inhibitor. Demonstration of two-step binding by rapid-kinetic studies of cystatin A labeled at the N-terminus with a fluorescent reporter group.
|
| |
Protein Sci, 9,
2218-2224.
|
 |
|
|
|
|
 |
R.Wubbolts,
and
J.Neefjes
(1999).
Intracellular transport and peptide loading of MHC class II molecules: regulation by chaperones and motors.
|
| |
Immunol Rev, 172,
189-208.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
| |